Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains delta-9-tetrahydrocannabinol (THC)...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic Variation Predicts Real-Time Δ <sup>9</sup> -tetrahydrocannabinol Response in Humans.

medRxiv : the preprint server for health sciences·2026
Same author

Cognitive, Electrophysiological, and Behavioral Presentation of First-Episode Psychosis With or Without Cannabis Exposure.

The American journal of psychiatry·2026
Same author

An opioid-withholding human laboratory paradigm during opioid agonist treatment for opioid use disorder and chronic pain: Phase- and dose-dependent effects of cannabidiol.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Baseline Mismatch Negativity Amplitude Predicts Direction and Magnitude of Ketamine Effect in Healthy Volunteers: A Disordinal Effect.

Biological psychiatry·2026
Same author

Optimized reference region and the effect on test-retest reliability and sensitivity to differences between Parkinson's disease and control groups with [<sup>11</sup>C]UCB-J.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·2026
Same author

Changes in cannabis use following legalization: Effects in first-episode psychosis.

Schizophrenia research·2026

Related Experiment Video

Updated: Jun 24, 2026

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

Cannabinoids and psychosis.

R Andrew Sewell1, Mohini Ranganathan, Deepak Cyril D'Souza

  • 1Psychiatry Service, VA Connecticut Healthcare System, West Haven, Connecticut 06516, USA.

International Review of Psychiatry (Abingdon, England)
|April 16, 2009
PubMed
Summary
This summary is machine-generated.

Cannabis use is linked to psychosis, increasing schizophrenia risk, especially with early exposure. While not a sole cause, cannabis interacts with other factors, potentially worsening existing psychotic disorders.

More Related Videos

Administration of &#916;9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

Related Experiment Videos

Last Updated: Jun 24, 2026

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

Administration of &#916;9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Cannabinoid receptor research has intensified the study of cannabis and psychosis.
  • Population surveys and case studies suggest a link between cannabis use and psychosis.
  • Longitudinal studies indicate early cannabis exposure nearly doubles schizophrenia risk.

Purpose of the Study:

  • To review the association between cannabis use and psychosis.
  • To examine cannabis's role in schizophrenia development and exacerbation.
  • To explore the interaction of cannabis with other risk factors for psychosis.

Main Methods:

  • Review of case series, surveys, cross-sectional, and longitudinal studies.
  • Analysis of pharmacological studies on cannabinoid effects.
  • Synthesis of evidence on cannabis impact on psychotic disorders.

Main Results:

  • Cannabis use is associated with psychotic symptoms and an increased risk of schizophrenia.
  • Cannabinoids can induce transient psychotic symptoms in healthy individuals.
  • Cannabis exposure can worsen symptoms and relapse in those with existing psychotic disorders.

Conclusions:

  • Cannabis is a 'component cause' of psychosis, interacting with other factors.
  • Individual vulnerability to cannabis-induced psychosis requires further investigation.
  • Biological mechanisms underlying cannabis-related psychosis risk need elucidation.